Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydrocortisone in Severe Hospital-acquired Pneumonia (HYDRO-SHIP)
NCT05354778Completed
- Sponsor
- IAMSPE
- Start
- Oct 2022
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) comparing Placebo with Hydrocortisone (2 arms). Primary endpoint: Early Clinical Failure at 7 days. Started Oct 2022; status: completed.
02
Drugs
hydrocortisone
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT05354778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05354778.